Biotech Values

[DewDiligence]

IMO, it’s likely that ENTA has quietly decided not to opt in for US profit sharing for the ABT-493/ABT-530 program and will instead take milestone payments and royalties from ABBV on US sales of ABT-493 as described in #msg-106500227.

(On ex-US sales of ABT-493, ENTA gets milestone payments and royalties from ABBV regardless of the opt-in decision for the US.)

If the above is correct, ENTA will probably announce its decision in the November PR reporting financial results for FY4Q14 (i.e. the quarter ending 9/30/14).